Replies to post #157221 on Biotech Values

[DewDiligence]

ASTM—I don’t follow the company, but the language you highlighted strikes me as innocuous. It sounds like the CEO is suggesting that an attempt will be made to use terminology more understandable to investors who don’t have a medical background.